Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cetuximab + PF-07799933 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cetuximab | Erbitux | IMC-C225 | EGFR Antibody 60 | Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov). |
PF-07799933 | PF07799933|PF 07799933|ARRY440|ARRY 440|ARRY-440 | BRAF Inhibitor 25 | PF-07799933 inhibits BRAF mutations, including class 1, 2, and 3 mutations, which potentially leads to decreased downstream Erk signaling and inhibition of tumor growth (PMID: 38691346). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05355701 | Phase I | Binimetinib + PF-07799933 PF-07799933 Cetuximab + PF-07799933 | A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | Recruiting | USA | ISR | CAN | 0 |